Table 1.
Summary of some of Raman based cancer nanotherapies currently being investigated.
| Therapy Type | Modality | Nanoparticles | Anticancer Drug | Raman Instrumentation |
Target | Reference |
|---|---|---|---|---|---|---|
| NP assisted theranostic platform |
Diagnostic in vivo molecular imaging |
FU/HA/PG- Coated- PLGA- Encapsulated Iron oxide |
Epigallocatechin gallate (EGCG) |
T2-weighed MRI and in vivo imaging system-CT |
Orthotopic mouse model of prostate cancer |
[43] |
|
Therapeutic Activated Nanoparticle anticancer drug delivery |
FU/HA/PG- Coated- PLGA |
Fluorescence microscopy and Confocal spontaneous Raman Microscopy (excitation at 488 nm and emission at 525 nm) |
||||
| NP assisted theranostic platform |
Diagnostic Raman bioimaging |
Au nanostars-1 | No | Confocal Spontaneous Raman Microscopy (λ = 633 nm) |
Orthotopic mouse model of breast cancer |
[48] |
|
Therapeutic tumour ablation |
Au nanostars-2 | No | Photothermal Therapy (λ = 808 nm; density = 1 W/cm2; thermographs recorded with a NIR camera at intervals of 5 s) |
|||
| NP-free theranostic platform |
Diagnostic Raman bioimaging |
No | No | Spontaneous Raman Microscopy (λ = 785 nm; laser power on sample ~80 mW; integration time = 10 s; number of spectra acquired for each cell = 5) |
Colorectal tumour xenografts in nu/nu mice |
[49] |
|
Therapeutic Photodynamic therapy |
No | No | Photosensitiser 5-ALA and laser source (λ = 785 nm) |